Hepatitis C virus(HCV) is a potent human pathogen and is one of the main causes of chronic hepatitis round the world. The present review describes the evidencebased consensus on the diagnosis, prevention and managemen...Hepatitis C virus(HCV) is a potent human pathogen and is one of the main causes of chronic hepatitis round the world. The present review describes the evidencebased consensus on the diagnosis, prevention and management of HCV disease. Various techniques, for the detection of anti-HCV immunoglobulin G immunoassays, detection of HCV RNA by identifying virus-specific molecules nucleic acid testings, recognition of core antigen for diagnosis of HCV, quantitative antigenassay, have been used to detect HCV RNA and core antigen. Advanced technologies such as nanoparticlebased diagnostic assays, loop-mediated isothermal amplification and aptamers and Ortho trak-C assay have also come to the front that provides best detection results with greater ease and specificity for detection of HCV. It is of immense importance to prevent this infection especially among the sexual partners, injecting drug users, mother-to-infant transmission of HCV, household contact, healthcare workers and people who get tattoos and piercing on their skin. Management of this infection is intended to eradicate it out of the body of patients. Management includes examining the treatment(efficacy and protection), assessment of hepatic condition before commencing therapy, controlling the parameters upon which dual and triple therapies work, monitoring the body after treatment and adjusting the co-factors. Examining the treatment in some special groups of people(HIV/HCV co-infected, hemodialysis patients, renal transplanted patients).展开更多
目的研制乙型肝炎病毒(hepatitis B virus,HBV)核酸血筛试剂国家参考品。方法将从上海、甘肃、河南、湖南、湖北等地域的血液中心、浆站、生物制品公司等收集到的多份人HBV抗体阳性或HBV感染者血浆样品,经HBV DNA病毒检测,筛选出阴性及...目的研制乙型肝炎病毒(hepatitis B virus,HBV)核酸血筛试剂国家参考品。方法将从上海、甘肃、河南、湖南、湖北等地域的血液中心、浆站、生物制品公司等收集到的多份人HBV抗体阳性或HBV感染者血浆样品,经HBV DNA病毒检测,筛选出阴性及阳性参考品候选品;将HBV DNA国家标准品用人阴性血浆稀释至10^(3)IU/mL,作为最低检出量(limit of detection,LOD)候选品。将HBV核酸血筛国家阴性及阳性参考品候选品、LOD参考品待标品分发至8家企业实验室,分别进行HBVHCVHIV核酸血筛联检测定。对整套国家参考品进行均匀性和稳定性考察。结果共筛选出8份HBV病毒载量为0的阴性样品,作为阴性参考品;9份HBV DNA病毒载量为10^(3)~10^(4)IU/mL的阳性样品,作为阳性参考品;1份LOD参考品,经WHO HBV DNA标准品标定,病毒含量为1.0×10^(3)IU/mL。整套国家参考品稳定性好,均匀性检查符合规定。结论制备了HBV核酸血筛试剂国家参考品,为我国HBV核酸血筛试剂的质量控制和标准化提供了依据。展开更多
文摘Hepatitis C virus(HCV) is a potent human pathogen and is one of the main causes of chronic hepatitis round the world. The present review describes the evidencebased consensus on the diagnosis, prevention and management of HCV disease. Various techniques, for the detection of anti-HCV immunoglobulin G immunoassays, detection of HCV RNA by identifying virus-specific molecules nucleic acid testings, recognition of core antigen for diagnosis of HCV, quantitative antigenassay, have been used to detect HCV RNA and core antigen. Advanced technologies such as nanoparticlebased diagnostic assays, loop-mediated isothermal amplification and aptamers and Ortho trak-C assay have also come to the front that provides best detection results with greater ease and specificity for detection of HCV. It is of immense importance to prevent this infection especially among the sexual partners, injecting drug users, mother-to-infant transmission of HCV, household contact, healthcare workers and people who get tattoos and piercing on their skin. Management of this infection is intended to eradicate it out of the body of patients. Management includes examining the treatment(efficacy and protection), assessment of hepatic condition before commencing therapy, controlling the parameters upon which dual and triple therapies work, monitoring the body after treatment and adjusting the co-factors. Examining the treatment in some special groups of people(HIV/HCV co-infected, hemodialysis patients, renal transplanted patients).
文摘目的研制乙型肝炎病毒(hepatitis B virus,HBV)核酸血筛试剂国家参考品。方法将从上海、甘肃、河南、湖南、湖北等地域的血液中心、浆站、生物制品公司等收集到的多份人HBV抗体阳性或HBV感染者血浆样品,经HBV DNA病毒检测,筛选出阴性及阳性参考品候选品;将HBV DNA国家标准品用人阴性血浆稀释至10^(3)IU/mL,作为最低检出量(limit of detection,LOD)候选品。将HBV核酸血筛国家阴性及阳性参考品候选品、LOD参考品待标品分发至8家企业实验室,分别进行HBVHCVHIV核酸血筛联检测定。对整套国家参考品进行均匀性和稳定性考察。结果共筛选出8份HBV病毒载量为0的阴性样品,作为阴性参考品;9份HBV DNA病毒载量为10^(3)~10^(4)IU/mL的阳性样品,作为阳性参考品;1份LOD参考品,经WHO HBV DNA标准品标定,病毒含量为1.0×10^(3)IU/mL。整套国家参考品稳定性好,均匀性检查符合规定。结论制备了HBV核酸血筛试剂国家参考品,为我国HBV核酸血筛试剂的质量控制和标准化提供了依据。
